Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 42 entries
Sorted by: Best Match Show Resources per page
Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry.

Open heart

Kalkman DN, Woudstra P, Menown IBA, den Heijer P, Van't Hof AW, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, Muller P, Tijssen JG, Beijk MAM, de Winter RJ.
PMID: 28761685
Open Heart. 2017 Jul 11;4(2):e000634. doi: 10.1136/openhrt-2017-000634. eCollection 2017.

OBJECTIVE: The dual-therapy stent combines an abluminal biodegradable drug-eluting coating, with a 'pro-healing' luminal layer. This bioengineered layer attracts circulating endothelial progenitor cells that can differentiate into normal endothelium. Rapid endothelialisation of the stent might allow safe short dual...

Cite
Kalkman DN, Woudstra P, Menown IBA, et al. Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart. 2017;4(2):e000634doi: 10.1136/openhrt-2017-000634.
Kalkman, D. N., Woudstra, P., Menown, I. B. A., den Heijer, P., Van't Hof, A. W., Erglis, A., Suryapranata, H., Arkenbout, K. E., Iñiguez, A., Muller, P., Tijssen, J. G., Beijk, M. A. M., & de Winter, R. J. (2017). Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open heart, 4(2), e000634. https://doi.org/10.1136/openhrt-2017-000634
Kalkman, Deborah N, et al. "Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry." Open heart vol. 4,2 (2017): e000634. doi: https://doi.org/10.1136/openhrt-2017-000634
Kalkman DN, Woudstra P, Menown IBA, den Heijer P, Van't Hof AW, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, Muller P, Tijssen JG, Beijk MAM, de Winter RJ. Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart. 2017 Jul 11;4(2):e000634. doi: 10.1136/openhrt-2017-000634. eCollection 2017. PMID: 28761685; PMCID: PMC5515182.
Copy Download .nbib Format: NLM
Audit Reviewed. A Report from the Regions.

Journal of the Royal College of Physicians of London

Van't Hoff W.
PMID: 30667906
J R Coll Physicians Lond. 1981 Apr;15(2):135-136.

No abstract available.

Cite
Van't Hoff W. Audit Reviewed. A Report from the Regions. J R Coll Physicians Lond. 1981;15(2):135-136
Van't Hoff, W. (1981). Audit Reviewed. A Report from the Regions. Journal of the Royal College of Physicians of London, 15(2), 135-136.
Van't Hoff, Walter. "Audit Reviewed. A Report from the Regions." Journal of the Royal College of Physicians of London vol. 15,2 (1981): 135-136.
Van't Hoff W. Audit Reviewed. A Report from the Regions. J R Coll Physicians Lond. 1981 Apr;15(2):135-136. PMID: 30667906; PMCID: PMC5377664.
Copy Download .nbib Format: NLM
Getting across the plasma membrane and beyond: intracellular uses of colloidal semiconductor nanocrystals.

Journal of biomedicine & biotechnology

Luccardini C, Yakovlev A, Gaillard S, van 't Hoff M, Alberola AP, Mallet JM, Parak WJ, Feltz A, Oheim M.
PMID: 18273411
J Biomed Biotechnol. 2007;2007(7):68963. doi: 10.1155/2007/68963.

Semiconductor nanocrystals (NCs) are increasingly being used as photoluminescen markers in biological imaging. Their brightness, large Stokes shift, and high photostability compared to organic fluorophores permit the exploration of biological phenomena at the single-molecule scale with superior temporal resolution...

Cite
Luccardini C, Yakovlev A, Gaillard S, et al. Getting across the plasma membrane and beyond: intracellular uses of colloidal semiconductor nanocrystals. J Biomed Biotechnol. 2007;2007(7):68963doi: 10.1155/2007/68963.
Luccardini, C., Yakovlev, A., Gaillard, S., van 't Hoff, M., Alberola, A. P., Mallet, J. M., Parak, W. J., Feltz, A., & Oheim, M. (2007). Getting across the plasma membrane and beyond: intracellular uses of colloidal semiconductor nanocrystals. Journal of biomedicine & biotechnology, 2007(7), 68963. https://doi.org/10.1155/2007/68963
Luccardini, Camilla, et al. "Getting across the plasma membrane and beyond: intracellular uses of colloidal semiconductor nanocrystals." Journal of biomedicine & biotechnology vol. 2007,7 (2007): 68963. doi: https://doi.org/10.1155/2007/68963
Luccardini C, Yakovlev A, Gaillard S, van 't Hoff M, Alberola AP, Mallet JM, Parak WJ, Feltz A, Oheim M. Getting across the plasma membrane and beyond: intracellular uses of colloidal semiconductor nanocrystals. J Biomed Biotechnol. 2007;2007(7):68963. doi: 10.1155/2007/68963. PMID: 18273411; PMCID: PMC2217606.
Copy Download .nbib Format: NLM
Proximity of an ARS consensus sequence to a replication origin of pea (Pisum sativum).

Plant molecular biology

Hernández P, Bjerknes CA, Lamm SS, Van't Hof J.
PMID: 24277589
Plant Mol Biol. 1988 Sep;10(5):413-22. doi: 10.1007/BF00014947.

The replication origin (ori-r9) of the 9.0 kb rDNA repeats of pea (Pisum sativum, cv. Alaska) was cloned and found to reside in a 1.5 kb fragment of the non-transcribed spacer region located between the 25 S and 18...

Cite
Hernández P, Bjerknes CA, Lamm SS, et al. Proximity of an ARS consensus sequence to a replication origin of pea (Pisum sativum). Plant Mol Biol. 1988;10(5):413-22doi: 10.1007/BF00014947.
Hernández, P., Bjerknes, C. A., Lamm, S. S., & Van't Hof, J. (1988). Proximity of an ARS consensus sequence to a replication origin of pea (Pisum sativum). Plant molecular biology, 10(5), 413-22. https://doi.org/10.1007/BF00014947
Hernández, P, et al. "Proximity of an ARS consensus sequence to a replication origin of pea (Pisum sativum)." Plant molecular biology vol. 10,5 (1988): 413-22. doi: https://doi.org/10.1007/BF00014947
Hernández P, Bjerknes CA, Lamm SS, Van't Hof J. Proximity of an ARS consensus sequence to a replication origin of pea (Pisum sativum). Plant Mol Biol. 1988 Sep;10(5):413-22. doi: 10.1007/BF00014947. PMID: 24277589.
Copy Download .nbib Format: NLM
Development of the mental health cultural adaptation and contextualization for implementation (mhCACI) procedure: a systematic framework to prepare evidence-based psychological interventions for scaling.

Global mental health (Cambridge, England)

Sangraula M, Kohrt BA, Ghimire R, Shrestha P, Luitel NP, Van't Hof E, Dawson K, Jordans MJD.
PMID: 33996110
Glob Ment Health (Camb). 2021 Feb 19;8:e6. doi: 10.1017/gmh.2021.5. eCollection 2021.

BACKGROUND: Because of the high burden of untreated mental illness in humanitarian settings and low- and middle-income countries, scaling-up effective psychological interventions require a cultural adaptation process that is feasible and acceptable. Our adaptation process incorporates changes into both...

Cite
Sangraula M, Kohrt BA, Ghimire R, et al. Development of the mental health cultural adaptation and contextualization for implementation (mhCACI) procedure: a systematic framework to prepare evidence-based psychological interventions for scaling. Glob Ment Health (Camb). 2021;8:e6doi: 10.1017/gmh.2021.5.
Sangraula, M., Kohrt, B. A., Ghimire, R., Shrestha, P., Luitel, N. P., Van't Hof, E., Dawson, K., & Jordans, M. J. D. (2021). Development of the mental health cultural adaptation and contextualization for implementation (mhCACI) procedure: a systematic framework to prepare evidence-based psychological interventions for scaling. Global mental health (Cambridge, England), 8e6. https://doi.org/10.1017/gmh.2021.5
Sangraula, Manaswi, et al. "Development of the mental health cultural adaptation and contextualization for implementation (mhCACI) procedure: a systematic framework to prepare evidence-based psychological interventions for scaling." Global mental health (Cambridge, England) vol. 8 (2021): e6. doi: https://doi.org/10.1017/gmh.2021.5
Sangraula M, Kohrt BA, Ghimire R, Shrestha P, Luitel NP, Van't Hof E, Dawson K, Jordans MJD. Development of the mental health cultural adaptation and contextualization for implementation (mhCACI) procedure: a systematic framework to prepare evidence-based psychological interventions for scaling. Glob Ment Health (Camb). 2021 Feb 19;8:e6. doi: 10.1017/gmh.2021.5. eCollection 2021. PMID: 33996110; PMCID: PMC8082944.
Copy Download .nbib Format: NLM
Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity.

Stem cells (Dayton, Ohio)

Metheny L, Eid S, Wuttisarnwattana P, Auletta JJ, Liu C, Van Dervort A, Paez C, Lee Z, Wilson D, Lazarus HM, Deans R, Vant Hof W, Ktena Y, Cooke KR.
PMID: 34255899
Stem Cells. 2021 Nov;39(11):1506-1519. doi: 10.1002/stem.3434. Epub 2021 Jul 28.

Graft-vs-host disease (GvHD) limits successful outcomes following allogeneic blood and marrow transplantation (allo-BMT). We examined whether the administration of human, bone marrow-derived, multipotent adult progenitor cells (MAPCs™) could regulate experimental GvHD. The immunoregulatory capacity of MAPC cells was evaluated...

Cite
Metheny L, Eid S, Wuttisarnwattana P, et al. Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity. Stem Cells. 2021;39(11):1506-1519doi: 10.1002/stem.3434.
Metheny, L., Eid, S., Wuttisarnwattana, P., Auletta, J. J., Liu, C., Van Dervort, A., Paez, C., Lee, Z., Wilson, D., Lazarus, H. M., Deans, R., Vant Hof, W., Ktena, Y., & Cooke, K. R. (2021). Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity. Stem cells (Dayton, Ohio), 39(11), 1506-1519. https://doi.org/10.1002/stem.3434
Metheny, Leland, et al. "Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity." Stem cells (Dayton, Ohio) vol. 39,11 (2021): 1506-1519. doi: https://doi.org/10.1002/stem.3434
Metheny L, Eid S, Wuttisarnwattana P, Auletta JJ, Liu C, Van Dervort A, Paez C, Lee Z, Wilson D, Lazarus HM, Deans R, Vant Hof W, Ktena Y, Cooke KR. Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity. Stem Cells. 2021 Nov;39(11):1506-1519. doi: 10.1002/stem.3434. Epub 2021 Jul 28. PMID: 34255899; PMCID: PMC8596993.
Copy Download .nbib Format: NLM
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.

Clinical journal of the American Society of Nephrology : CJASN

Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P.
PMID: 33985991
Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13.

BACKGROUND AND OBJECTIVES: In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production. The...

Cite
Frishberg Y, Deschênes G, Groothoff JW, et al. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021;16(7):1025-1036doi: 10.2215/CJN.14730920.
Frishberg, Y., Deschênes, G., Groothoff, J. W., Hulton, S. A., Magen, D., Harambat, J., Van't Hoff, W. G., Lorch, U., Milliner, D. S., Lieske, J. C., Haslett, P., Garg, P. P., Vaishnaw, A. K., Talamudupula, S., Lu, J., Habtemariam, B. A., Erbe, D. V., McGregor, T. L., Cochat, P. (2021). Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clinical journal of the American Society of Nephrology : CJASN, 16(7), 1025-1036. https://doi.org/10.2215/CJN.14730920
Frishberg, Yaacov, et al. "Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial." Clinical journal of the American Society of Nephrology : CJASN vol. 16,7 (2021): 1025-1036. doi: https://doi.org/10.2215/CJN.14730920
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. PMID: 33985991; PMCID: PMC8425611.
Copy Download .nbib Format: NLM
Erratum to: Clinical and molecular aspects of distal renal tubular acidosis in children.

Pediatric nephrology (Berlin, Germany)

Besouw MTP, Bienias M, Walsh P, Kleta R, Van't Hoff WG, Ashton E, Jenkins L, Bockenhauer D.
PMID: 28258487
Pediatr Nephrol. 2017 Jun;32(6):1095. doi: 10.1007/s00467-017-3631-6.

No abstract available.

Cite
Besouw MTP, Bienias M, Walsh P, et al. Erratum to: Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr Nephrol. 2017;32(6):1095doi: 10.1007/s00467-017-3631-6.
Besouw, M. T. P., Bienias, M., Walsh, P., Kleta, R., Van't Hoff, W. G., Ashton, E., Jenkins, L., & Bockenhauer, D. (2017). Erratum to: Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatric nephrology (Berlin, Germany), 32(6), 1095. https://doi.org/10.1007/s00467-017-3631-6
Besouw, Martine T P, et al. "Erratum to: Clinical and molecular aspects of distal renal tubular acidosis in children." Pediatric nephrology (Berlin, Germany) vol. 32,6 (2017): 1095. doi: https://doi.org/10.1007/s00467-017-3631-6
Besouw MTP, Bienias M, Walsh P, Kleta R, Van't Hoff WG, Ashton E, Jenkins L, Bockenhauer D. Erratum to: Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr Nephrol. 2017 Jun;32(6):1095. doi: 10.1007/s00467-017-3631-6. PMID: 28258487.
Copy Download .nbib Format: NLM
Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.

Future cardiology

van Werkum JW, Hackeng CM, Smit JJ, Van't Hof AW, Verheugt FW, Ten Berg JM.
PMID: 19804271
Future Cardiol. 2008 Jan;4(1):33-55. doi: 10.2217/14796678.4.1.33.

Multiple studies have demonstrated that subgroups of patients receiving combination therapy with aspirin and clopidogrel fail to produce the anticipated antiplatelet effect, and various terms such as 'aspirin resistance', 'clopidogrel resistance', 'heightened post-treatment platelet reactivity' and 'residual platelet reactivity'...

Cite
van Werkum JW, Hackeng CM, Smit JJ, et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol. 2008;4(1):33-55doi: 10.2217/14796678.4.1.33.
van Werkum, J. W., Hackeng, C. M., Smit, J. J., Van't Hof, A. W., Verheugt, F. W., & Ten Berg, J. M. (2008). Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future cardiology, 4(1), 33-55. https://doi.org/10.2217/14796678.4.1.33
van Werkum, Jochem W, et al. "Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence." Future cardiology vol. 4,1 (2008): 33-55. doi: https://doi.org/10.2217/14796678.4.1.33
van Werkum JW, Hackeng CM, Smit JJ, Van't Hof AW, Verheugt FW, Ten Berg JM. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol. 2008 Jan;4(1):33-55. doi: 10.2217/14796678.4.1.33. PMID: 19804271.
Copy Download .nbib Format: NLM
A programmable light engine for quantitative single molecule TIRF and HILO imaging.

Optics express

van 't Hoff M, de Sars V, Oheim M.
PMID: 18958128
Opt Express. 2008 Oct 27;16(22):18495-504. doi: 10.1364/oe.16.018495.

We report on a simple yet powerful implementation of objective-type total internal reflection fluorescence (TIRF) and highly inclined and laminated optical sheet (HILO, a type of dark-field) illumination. Instead of focusing the illuminating laser beam to a single spot...

Cite
van 't Hoff M, de Sars V, Oheim M. A programmable light engine for quantitative single molecule TIRF and HILO imaging. Opt Express. 2008;16(22):18495-504doi: 10.1364/oe.16.018495.
van 't Hoff, M., de Sars, V., & Oheim, M. (2008). A programmable light engine for quantitative single molecule TIRF and HILO imaging. Optics express, 16(22), 18495-504. https://doi.org/10.1364/oe.16.018495
van 't Hoff, Marcel, et al. "A programmable light engine for quantitative single molecule TIRF and HILO imaging." Optics express vol. 16,22 (2008): 18495-504. doi: https://doi.org/10.1364/oe.16.018495
van 't Hoff M, de Sars V, Oheim M. A programmable light engine for quantitative single molecule TIRF and HILO imaging. Opt Express. 2008 Oct 27;16(22):18495-504. doi: 10.1364/oe.16.018495. PMID: 18958128.
Copy Download .nbib Format: NLM
THE RELATION OF PHYSICAL CHEMISTRY TO PHYSICS AND CHEMISTRY.

Science (New York, N.Y.)

Van't Hoff JH.
PMID: 17797576
Science. 1905 Nov 24;22(569):649-54. doi: 10.1126/science.22.569.649.

No abstract available.

Cite
Van't Hoff JH. THE RELATION OF PHYSICAL CHEMISTRY TO PHYSICS AND CHEMISTRY. Science. 1905;22(569):649-54doi: 10.1126/science.22.569.649.
Van't Hoff, J. H. (1905). THE RELATION OF PHYSICAL CHEMISTRY TO PHYSICS AND CHEMISTRY. Science (New York, N.Y.), 22(569), 649-54. https://doi.org/10.1126/science.22.569.649
Van't Hoff, J H. "THE RELATION OF PHYSICAL CHEMISTRY TO PHYSICS AND CHEMISTRY." Science (New York, N.Y.) vol. 22,569 (1905): 649-54. doi: https://doi.org/10.1126/science.22.569.649
Van't Hoff JH. THE RELATION OF PHYSICAL CHEMISTRY TO PHYSICS AND CHEMISTRY. Science. 1905 Nov 24;22(569):649-54. doi: 10.1126/science.22.569.649. PMID: 17797576.
Copy Download .nbib Format: NLM
[Health care for prisoners with mental health problems in Holland].

Revista espanola de sanidad penitenciaria

Van't Hoff G, de Looff J, Latooij H.
PMID: 23128410
Rev Esp Sanid Penit. 2009 Jun;11(1):24-30. doi: 10.4321/S1575-06202009000100005.

In this study, a general picture is given of prisoners needing health care as a result of mental disorder and who, for this reason, have been interned in special care units with different security levels. Prisoners with mental disorders...

Cite
Van't Hoff G, de Looff J, Latooij H. Asistencia de los reclusos con problemas de salud mental en Holanda. [Health care for prisoners with mental health problems in Holland]. Rev Esp Sanid Penit. 2009;11(1):24-30doi: 10.4321/S1575-06202009000100005.
Van't Hoff, G., de Looff, J., & Latooij, H. (2009). Asistencia de los reclusos con problemas de salud mental en Holanda. [Health care for prisoners with mental health problems in Holland]. Revista espanola de sanidad penitenciaria, 11(1), 24-30. https://doi.org/10.4321/S1575-06202009000100005
Van't Hoff, G, et al. "Asistencia de los reclusos con problemas de salud mental en Holanda." [Health care for prisoners with mental health problems in Holland]. Revista espanola de sanidad penitenciaria vol. 11,1 (2009): 24-30. doi: https://doi.org/10.4321/S1575-06202009000100005
Van't Hoff G, de Looff J, Latooij H. Asistencia de los reclusos con problemas de salud mental en Holanda. [Health care for prisoners with mental health problems in Holland]. Rev Esp Sanid Penit. 2009 Jun;11(1):24-30. doi: 10.4321/S1575-06202009000100005. Spanish. PMID: 23128410.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 42 entries